Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT

Sun Pharmaceutical Industries Limited today announced the company will share updated long-term efficacy and safety results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) and metastatic CSCC (mCSCC) expansion cohorts from the pivotal CK-301-101 trial of UNLOXCYT (cosibelimab-ipdl) at the European Society for Medical Oncology (ESMO) Congress on October 24, 2026 in Madrid, Spain. Cutaneous squamous cell carcinoma (CSCC) is among the most common skin cancers worldwide. While early stages are treatable, an estimated 40,000 US patients each year progress to advanced disease, resulting in nearly 15,000 deaths. Opinion : This news will have neutral effect on the stock price. Disclaimer : I do not hold this stock. This is not a buy,sell or hold recommendation.